SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).

Andrea Park

Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.

A new partnership between public and private sector institutions aims to advance the adoption of personalised healthcare in Singapore; part of this includes precision oncology for personalised cancer care.

Singapore Translational Cancer Consortium, National Cancer Centre Singapore, National University Hospital and Roche signed a Memorandum of Understanding (MOU) to leverage data insights and deepen understanding of unique drivers of disease to help improve health outcomes

Biomedical research is overseen by numerous Institutional Review Boards (IRBs) in Singapore but there has been no research that examines how the research review process is perceived by the local research community nor is there any systematic data on perceptions regarding the review process or other research ethics processes and IRB characteristics.

A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors.

This expert opinion review examines the key challenges to the clinical adoption of NGS-based diagnostics in Singapore, provides recommendations on impactful initiatives to improve adoption, and also offers practical guidance on specific cancer types in which NGS-based diagnostics are appropriate for use in Singapore.